Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis (Businesswire) - Nov 30, 2022 - "Aurinia Pharmaceuticals...announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).....The marketing authorization by the MHRA, which follows the European Commission (EC) authorization on September 19, 2022, is based on the Phase 3 AURORA 1 study and the AURORA 2 continuation study..."
European regulatory • Lupus • Lupus Nephritis
|